Structural Implications for Selective Targeting of PARPs.
about
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionDiscovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2 H )-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 InhibitorsEpigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.Family-wide analysis of poly(ADP-ribose) polymerase activityNew facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases.Poly(ADP-ribose) polymerase-13 and RNA regulation in immunity and cancer.Virus-Host Interactions and the ARTD/PARP Family of EnzymesPARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling PathwayPoly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cellsCTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degenerationADPriboDB: The database of ADP-ribosylated proteins.PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes.The rise and fall of poly(ADP-ribose): An enzymatic perspective.Molecular inhibitors of DNA repair: searching for the ultimate tumor killing weapon.Inhibition of poly(adenosine diphosphate-ribose) polymerase using quinazolinone nucleus.The Promise of Proteomics for the Study of ADP-RibosylationThe emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.Stalled replication forks within heterochromatin require ATRX for protection.Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain.Enhancing the efficacy of radiation therapy: premises, promises, and practicality.Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains.Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.Selective targeting of PARP-1 zinc finger recognition domains with Au(iii) organometallics.Comparative inhibitory profile and distribution of bacterial PARPs, using Clostridioides difficile CD160 PARP as a model.
P2860
Q26851765-D009A19C-6DAA-4DF6-851F-F5ECABA0C969Q27684311-D61524B1-CC11-4EBC-AFC6-1BE30DB03F76Q33886191-15BDCA90-5183-42F1-8E4A-A164D2CA1AF0Q34009850-7421423C-19A7-495D-9BF1-0CA66CC28065Q34042969-407B12B2-8A82-4FA8-83AA-59B74F7F2EA2Q35691217-48AE54FD-3769-48AF-AE92-35E9CF4135D5Q35968729-18802528-3C09-4666-BD99-1C520599B6BAQ36247467-1E7CFD64-9B8E-4F6F-9607-C65C64F56956Q36251670-27C786A8-FA3D-428B-8AFB-59CA59200E4CQ37173597-75B21F71-0450-48B9-AB4F-ADCCD93EB71AQ37526029-B8628698-8CE1-4053-9941-9537A44067F4Q37556937-0BBAC6E9-2EC2-40BA-8090-A045195571D0Q37661664-70E10E39-BC8A-487A-B3FE-99F0772FF900Q38473760-60BA9775-8299-4D3A-A165-1C944AF1CB8EQ38573619-A54D844B-B168-4E5B-B703-3CC15D8F34ECQ38911909-100C1A15-14DF-4709-8A62-88907BDD3F87Q38993857-D2AE84DB-E9A7-4502-93A7-8DD766451F7BQ39190147-6331A5C1-747F-422D-83DA-B7D3D453E3B8Q40220408-60654237-83BB-40AF-A1A0-59607CCE76C1Q41133627-CDD704F9-4520-4BB3-93C7-1CCCC46C8FA8Q41316932-D3DA21B0-E85E-4814-B2FA-39BBB97C6AAFQ41539026-038AEA37-06E6-4F90-B050-9B79CCE2E008Q41924768-7C90B74C-555F-407E-8F18-345137DAA3A9Q42072170-6F6DFD80-13FB-4CB2-9E76-4022C766B9BEQ42095016-790B7595-DA38-40E4-B803-8BAFC86EAF2DQ42545565-B46D83AE-F31B-4874-9E19-B25EDC7912E9Q47131999-8EB69017-D512-4F05-910A-D1E06385D9D5Q50333817-68BEDE68-2482-46AB-99A5-515C67A54D76Q50902460-D9DD493A-7801-4055-8F6D-3AE9F1AA887AQ51529685-34F30E74-F9AA-49EF-B91D-53D550A45CF3Q52401743-4C940840-D272-49EA-9092-53F174D3BAA5Q54940157-C99583E7-26B6-4A2E-AC69-BED999EF81B5
P2860
Structural Implications for Selective Targeting of PARPs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Structural Implications for Selective Targeting of PARPs.
@en
Structural Implications for Selective Targeting of PARPs.
@nl
type
label
Structural Implications for Selective Targeting of PARPs.
@en
Structural Implications for Selective Targeting of PARPs.
@nl
prefLabel
Structural Implications for Selective Targeting of PARPs.
@en
Structural Implications for Selective Targeting of PARPs.
@nl
P2093
P2860
P356
P1476
Structural Implications for Selective Targeting of PARPs.
@en
P2093
Jamin D Steffen
John M Pascal
Jonathan R Brody
Roger S Armen
P2860
P356
10.3389/FONC.2013.00301
P577
2013-12-20T00:00:00Z